MARKET

CLRB

CLRB

Cellectar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.240
+0.010
+0.81%
After Hours: 1.270 +0.03 +2.42% 17:18 10/19 EDT
OPEN
1.240
PREV CLOSE
1.230
HIGH
1.250
LOW
1.210
VOLUME
106.29K
TURNOVER
--
52 WEEK HIGH
3.330
52 WEEK LOW
1.010
MARKET CAP
33.02M
P/E (TTM)
-0.8501
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cellectar Biosciences Phase 2 Data In Multiple Myeloma Is Worth A Look
CLRB's CLR131 recorded a 40% ORR in a Phase 2 Multiple Myeloma study (granted 6 of 15 patients). KPTI's Xpovio was approved for Multiple Myeloma with a lower ORR.At $1.15/share CLRB's market cap is just over $30MM and with $20MM+ cash on hand at June 30, 2020 CLRB's enterprise value is only ~$10MM.A $20MM June 2020 financing raised enough money to fund CLRB through the end of 2021.CLRB's investor presentation notes the company is open to an acquisition in the near term.Like many clinical stage oncology biotechs, CLRB's share price is down 30%+ since July (CLRB closed at $1.66 on July 31, 2020) even after releasing the positive data.
Seekingalpha · 09/14 17:40
Cellectar Biosciences to Present at Two Upcoming Investor Conferences
FLORHAM PARK, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced James Caruso, president and CEO, will present
GlobeNewswire · 09/10 12:00
Cellectar Reports Data On CLR 131 Phase 2 CLOVER-1 Stuy In Triple Class Refractory Multiple Myeloma Patients; Reports A 'Clinically Meaningful 40% Overall Response Rate Was Observed'
Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ:CLRB), a
Benzinga · 09/09 12:14
Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients
40% overall response rate (ORR) with a total administered dose of 60 mCi or greaterFLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the
GlobeNewswire · 09/09 12:00
Cellectar Presents Poster at the AACR VIRTUAL MEETING: ADVANCES IN MALIGNANT LYMPHOMA
GlobeNewswire · 08/17 15:01
Cellectar Presents Poster At AACR Virtual Meeting Titled 'ADVANCES IN MALIGNANT LYMPHOMA'
Benzinga · 08/17 14:07
GOLD, OSTK among premarket gainers
CureVac (CVAC) +47% on making reasonable profit on COVID-19 vaccine.LMP Automotive (LMPX) +42% on Q2 results.Microbot Medical (MBOT) +38% on successful study of surgical robot.Sonoma Pharmaceuticals (SNOA) +13% on FQ1 results.CooTek (CTK) +19%.Mustang Bio
Seekingalpha · 08/17 12:35
Cellector Biosciences shares are trading lower after the company filed for a mixed shelf offering of up to $100 million.
Benzinga · 08/11 21:11
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLRB. Analyze the recent business situations of Cellectar through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLRB stock price target is 5.57 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 36
Institutional Holdings: 3.81M
% Owned: 14.30%
Shares Outstanding: 26.63M
TypeInstitutionsShares
Increased
3
617.76K
New
15
933.50K
Decreased
2
11.00K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.40%
Pharmaceuticals & Medical Research
-1.74%
Key Executives
Chairman/Independent Director
Douglas Swirsky
President/Chief Executive Officer/Director
James Caruso
Chief Financial Officer/Vice President
Dov Elefant
Vice President
John Friend
Other
Jarrod Longcor
Independent Director
Frederick Driscoll
Independent Director
Stephen Hill
Independent Director
Stefan Loren
Independent Director
John Neis
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CLRB
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cellectar Biosciences Inc stock information, including NASDAQ:CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.